A Detail View of Single-Use Equipment Opportunities - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

A Detail View of Single-Use Equipment Opportunities
The authors propose increased use of single-use technologies in biopharmaceutical manufacturing to achieve operational excellence without compromising product quality.

Pharmaceutical Technology
Volume 34, pp. s16-s20

Technology-integration improvements

The "single-use" concept came loaded with huge expectations of finding new solutions to address the needs of the changing biopharmaceutical industry. Suppliers of single-use equipment have had difficulty living up to these expectations thus far, partly because the expectations were not properly defined and partly due to intellectual property (IP) and supply-chain issues.

Figure 3: Water-consumption percentage differences: Stainless steel versus single-use equipment (Data from Ref. 9).
In a hard-piped manufacturing process, the bioprocessing flow path is only qualified once. With single-use technology, a new flow path might be supplied various times, especially in multipurpose scenarios, and the qualification of the new flow's components is often in the hands of the supplier. The supplier is urged to provide disposable flow paths using the same components and properties for years to come.

To meet this request, however, the supplier must own all of the critical pieces of a particular assembly. For this reason, many suppliers are aligning with, or acquiring, component suppliers and IP owners. Unfortunately, a lack of standards and competition in this arena has promoted a vast array of equipment items, assemblies, and validation-procedure differences. These varieties, marketing-driven product and validation claims cause more insecurities and questions, than solid standardized solutions.

Promising new development, in the form of single-use unit operations, is moving away from isolated technical solutions and toward new, highly-integrated concepts. End-users of disposable bags for media initiated this trend in an effort to move from a fixed process to a single-use process that includes mixing, filtration, temperature, recipe, and level control.

The integration of disposable sensors helped develop fully-disposable, cell-culture systems and opened the door for single-use applications for most of the unit operations within a manufacturing process. New approaches are supplying single-use technology platforms along the typical manufacturing process.

The application know-how determines the design of those platforms, but standardization of components such as tubing and connectors, ensures interconnectivity at the same time. These concepts allow a clean and streamlined process with a unified automation, control, and validation concept and, finally, a high level of operational excellence and security.

The single-use approach demands the highest level of technology integration possible. However, the economic and operational advantages of the disposable option apply mostly to Green Field Facilities (i.e., facilities planned from scratch) with high-value, low-volume products and might not be an option for existing manufacturing processes. This restriction to new facility design is a purely economical one as most of the capital investments within existing processes are made and the equipment is written off. Nevertheless, the flexibility of single-use manufacturing philosophy is attractive for expansion projects within existing facilities. In addition, so-called "hybrid" systems merge the best out of both worlds by integrating single-use unit operations such as buffer and media-hold steps, into existing production facilities.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here